Skip to main content

Table 1 Demographic, clinical and serological characteristics of patients with pSS-related TIN and GMN

From: Clinical significance of C4d deposition in renal tissues from patients with primary Sjögren’s syndrome—a preliminary study

Items Total (n = 39) TIN (n = 21) GMN (n = 18) P
Age at KB (years, M ± SD) 42 ± 14.1 36 ± 12.5 48 ± 13.5 0.008
Male:female ratio 9/30 3/18 6/12 NS
PSS duration (years, IQR) 5.0 [2.0, 16.0] 3.0 [1.75, 7.50] 11.5 [2.0, 20.0] 0.025
IS therapy (%) 15/39 (38.5) 8/21 7/18 NS
ANA (+) (%) 37/39 (94.9) 21/21 16/18 NS
 ANA 1:1280 (+) (%) 8/39 (20.5) 5/21 3/18 NS
 ANA 1:640 (+) (%) 16/39 (41.0) 11/21 5/18 NS
Anti-SSA (+) (%) 34/39 (87.2) 18/21 16/18 NS
Anti-SSB (+) (%) 13/39 (33.3) 9/21 4/18 NS
Serum IgG elevation (%) 25/38 (65.8) 17/20 8/18 0.016
Serum IgA elevation (%) 14/38 (36.8) 6/20 8/18 NS
Serum IgM elevation (%) 4/38 (10.5) 3/20 1/18 NS
HypocomplementemiaLow CH50 3/38 (7.9) 0/20 3/18 NS
 Low C3 6/38 (15.8) 1/20 5/18 NS
 Low C4 6/35 (17.1) 2/17 4/18 NS
RTA(%) 22/39 (56.4) 20/21 2/18 < 0.001
Urinary calcification/stone (%) 12/39 (30.8) 10/21 2/18 0.018
Microhaematuria (%) 18/39 (46.2) 5/21 13/18 0.004
Proteinuria (%)
 Mild (< 1.5 g/day) 25/39 (64.1) 17/21 (81.0) 8/18 (44.4)  
 Moderate (1.5–3.5 g/day) 7/39 (17.9) 4/21 (19.0) 3/18 (16.7) 0.006
 Nephrotic range (> 3.5 g/day) 7/39 (17.9) 0/21 (0) 7/18 (38.9)  
24-h urine collection (g/day, M ± SD) 2.2 ± 3.7 0.8 ± 0.6 3.9 ± 4.9 0.033
Scr (μmol/L, M ± SD) 103.9 ± 40.99 113.2 ± 42.33 93.0 ± 37.60 NS
eGFR (mL/min.1.73 m2, M ± SD) 70.2 ± 27.23 64.0 ± 28.17 77.5 ± 24.90 NS
  1. NS not significant, TIN tubular interstitial nephritis, GMN glomerulonephritis, KB kidney biopsy, IS immunosuppression, ANA anti-nuclear antibodies, RTA renal tubular acidosis, Scr serum creatinine, eGFR estimated glomerular filtration rate (calculated with the CKD-EPI creatinine equation), M ± SD mean ± standard deviation, IQR interquartile range